Clinical Training 2011 - The 2010 FDA warning letters: Revealing the critical conduct areas in clinical studies

This 90-minute webinar will review FDA warning letters in Clinical Trials and present critical parameters to watch out for in order to secure compliance whether you are running or monitoring a clinical trial.

Whether you are a monitor or an investigator, word of an FDA inspection at your site is enough to make you wonder if everything has been done in compliance with the GCP guidelines.

This presentation will provide a cumulative review of the FDA warning letters of 2010 and help you identify the key conduct areas in clinical trials. When clustered, the findings that most frequently appear in warning letters are a measure of the severity of non compliance. We will show critical parameters to watch out for in order to secure compliance whether you are running or monitoring a clinical trial.This 90-minute webinar will review FDA warning letters in Clinical Trials and present critical parameters to watch out for in order to secure compliance whether you are running or monitoring a clinical trial.

By attending this webinar, you can identify and take control of areas that are usually prone to non-compliance and apply early, preventive action to secure your site or your study.